Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
ALTthis companyAltimmune, Inc.	$2.18	-3.61×	1.41×	7,757.46×	-3.56×	-96.0%	100.0%	-230461.0%	-214861.0%	-39.2%	-35.4%	-21.2%	0.16×	0.09×	-57.76×	18.55×	0.0%	2	2.76	2	C+
ABUSArbutus Biopharma Corp	$3.67	-28.29×	12.04×	65.44×	-27.47×	-163.1%	97.4%	-192.1%	-237.9%	-43.7%	-30.3%	-4.3%	0.05×	0.42×	-278.88×	15.73×	0.0%	5	28.57	4	A-
ALGSAligos Therapeutics, Inc.	$4.38	-3.8×	1.72×	42.14×	-3.45×	-97.4%	57.5%	-4024.9%	-1106.7%	-45.2%	-123.9%	-90.0%	0.1×	0.57×	0×	3.9×	0.0%	2	-16.11	2	C
ASMBAssembly Biosciences, Inc.	$20.95	-61.84×	1.84×	5.27×	-54.31×	-382.4%	99.8%	-16.8%	-8.5%	-3.0%	-5.8%	-10.8%	0.01×	9.31×	0×	5.22×	0.0%	2	7.22	2	B-
BMEABiomea Fusion, Inc.	$0.60	-1.05×	2.19×	0×	-0.17×	48.4%	0.0%	0.0%	0.0%	-209.1%	-166.2%	-108.7%	0.05×	0.9×	0×	5.23×	0.0%	0	-18.95	2	C+
ENTAEnanta Pharmaceuticals, Inc.	$11.49	-3.12×	3.95×	3.91×	-5.99×	-669.1%	93.0%	-130.7%	-125.4%	-126.5%	-31.4%	-12.6%	3.11×	-2.38×	-11.11×	4.21×	0.0%	3	-0.92	1	C-
Peer median	—	-3.8×	2.19×	5.27×	-5.99×	-163.1%	93.0%	-130.7%	-125.4%	-45.2%	-31.4%	-12.6%	0.05×	0.57×	0×	5.22×	0.0%	2	-0.92	2	—